Clinical Trials

Gadopentetate dimeglumine has been evaluated across Phase 1 through Phase 4 and observational clinical trials sponsored by academic, federal, and pharmaceutical organizations. Encompassing completed, active, and terminated protocols, these studies investigate diagnostic magnetic resonance imaging in structural and vascular pathologies such as pancreatic adenocarcinoma, brain neoplasms, renal artery stenosis, and liver fibrosis. Overall, this body of research underscores the agent's established utility in evaluating oncological, renal, and cardiovascular diseases.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00375830 COMPLETED
Cancer
Stanford University
2006-01 PHASE2
NCT02371798 WITHDRAWN
Meniere Disease
Emory University
2015-02
NCT02967380 TERMINATED
Adult Anaplastic (Malignant) Meningioma; Adult Anaplastic Astrocytoma; Adult Anaplastic Ependymoma; Adult Anaplastic Oligodendroglioma; Adult Brain Stem Glioma; Adult Choroid Plexus Neoplasm; Adult Diffuse Astrocytoma; Adult Ependymoblastoma; Adult Ependymoma; Adult Giant Cell Glioblastoma; Adult Glioblastoma; Adult Gliosarcoma; Adult Grade II Meningioma; Adult Medulloblastoma; Adult Mixed Glioma; Adult Oligodendroglioma; Adult Papillary Meningioma; Adult Pineal Gland Astrocytoma; Adult Pineoblastoma; Adult Primary Melanocytic Lesion of Meninges; Adult Supratentorial Primitive Neuroectodermal Tumor; Malignant Adult Intracranial Hemangiopericytoma; Metastatic Malignant Neoplasm in the Brain; Multiple Sclerosis; Recurrent Adult Brain Neoplasm
University of Southern California
2011-12-14
NCT02175069 COMPLETED
Disorder of Shoulder
Paracelsus Medical University
2013-12 PHASE4
NCT02080312 COMPLETED
Meniere's Disease
University of California, San Diego
2012-01
NCT02775786 Active not recruiting
Pancreatic Adenocarcinoma
Columbia University
2013-11 Not Applicable
NCT01416740 WITHDRAWN
Shoulder Pain
Milton S. Hershey Medical Center
2009-12
NCT01260636 COMPLETED
Carotid, Aortic, Renal or Peripheral Artery Disease
Bracco Diagnostics, Inc
2009-09 PHASE3
NCT01211873 COMPLETED
Diagnostic Self Evaluation; Central Nervous System Diseases
Guerbet
2010-09 PHASE3
NCT00060008 TERMINATED
Neurofibromatosis Type 1; Precancerous Condition
Children's Hospital of Philadelphia
2002-04
NCT01050829 COMPLETED
Magnetic Resonance Imaging
Bayer
2010-01 PHASE3
NCT00937391 COMPLETED
Magnetic Resonance Imaging
Bayer
2010-01 PHASE3
NCT00373152 WITHDRAWN
Breast Cancer
Masonic Cancer Center, University of Minnesota
2005-03 PHASE2
NCT00999258 Unknown status
Glomerular Filtration Rate|Chronic Allograft Nephropathy
Temple University|Wyeth is now a wholly owned subsidiary of Pfizer
2009-09 Phase 4
NCT00880061 Terminated
Brain Neoplasm|Glioma
National Institute of Neurological Disorders and Stroke (NINDS)|National Institutes of Health Clinical Center (CC)
2009-04-07 Phase 1
NCT00019604 TERMINATED
Liver Cancer; Metastatic Cancer; Unspecified Adult Solid Tumor, Protocol Specific
National Institutes of Health Clinical Center (CC)
1998-08 PHASE2
NCT00043017 COMPLETED
Breast Cancer
American College of Radiology Imaging Network
2002-05 PHASE2
NCT00652418 COMPLETED
Magnetic Resonance Angiography; Peripheral Vascular Diseases; Peripheral Arterial Diseases
Bayer
2004-07 PHASE2
NCT00004936 COMPLETED
Cervical Cancer
American College of Radiology Imaging Network
2000-04
NCT00005790 WITHDRAWN
Brain and Central Nervous System Tumors
Northwestern University
1996-04
NCT00310557 COMPLETED
Renal Artery Stenosis
Bayer
2003-12 PHASE3
NCT00310544 COMPLETED
Myocardial Infarction
Bayer
2006-03 PHASE2
NCT00310609 COMPLETED
Cardiovascular Abnormalities
Bayer
2003-12 PHASE3
NCT00309075 COMPLETED
Stenosis
Bayer
2003-12 PHASE3
NCT00310596 COMPLETED
Healthy
Bayer
2004-01 PHASE1
NCT00185276 COMPLETED
Peripheral Vascular Disease
Bayer
2003-03 PHASE3

(data from https://clinicaltrials.gov, updated on 2023-12-12)

Check the Gadopentetate Dimeglumine product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

As an extracellular paramagnetic contrast agent, gadopentetate dimeglumine shortens local T1 and T2 relaxation times by interacting with surrounding water hydrogen protons upon intravenous administration. This acceleration of magnetic relaxation enhances tissue signal intensity during magnetic resonance imaging, enabling precise visualization of vascular permeability and anatomical features to assist in evaluating clinical conditions such as pancreatic adenocarcinoma, brain neoplasms, and renal insufficiency.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.